Gossamer Bio Completes 1-for-80 Reverse Split to Regain Nasdaq Compliance
GOSS is trading near its 52-week low of $9.104 (98% below the low).
Summary
Gossamer Bio completed its 1-for-80 reverse stock split effective September 10, 2026, cutting authorized shares from 4 billion to 50 million in a bid to regain Nasdaq's $1.00 minimum bid compliance by October 5, 2026.
Key Events · Corporate Governance and Compliance · GOSS
-
Reverse Split Effective
The 1-for-80 reverse stock split became effective at 11:59 p.m. ET on September 10, 2026, with split-adjusted trading beginning September 11, 2026 under new CUSIP 38341P 201.
-
Authorized Shares Cut
Authorized common shares reduced from 4,000,000,000 to 50,000,000; total authorized capital stock reduced from 4,070,000,000 to 120,000,000.
-
Nasdaq Compliance Deadline
The company must maintain a closing bid price of at least $1.00 for 10 consecutive business days before October 5, 2026 to regain Nasdaq compliance.
-
Going Concern Context
This reverse split follows the Q2 2026 10-Q going-concern warning and Nasdaq delisting risk; cash runway extends only into Q1 2027.
Analysis · GOSS · Life Sciences
Gossamer Bio's 1-for-80 reverse stock split became effective on September 10, 2026, reducing authorized common shares from 4 billion to 50 million. The move is designed to lift the stock price above the $1.00 Nasdaq minimum bid requirement before the October 5, 2026 compliance deadline. With the company already under a going-concern warning and facing delisting risk, this reverse split is a critical step to maintain its listing — but it does not address the underlying cash runway that extends only into Q1 2027.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOSS was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.6M. The 52-week trading range was $9.10 to $309.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.